Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial

Introduction Rare solid tumors account for one-quarter of cancers among adults in the United States, but few resources have been devoted to their treatment. We evaluated the efficacy of pembrolizumab, a programmed cell death-1 inhibitor, in patients with rare solid tumors. Methods We conducted a pha...

Full description

Saved in:
Bibliographic Details
Main Authors: Mirella Nardo, Camila Braganca Xavier, Bettzy Stephen, Jeffrey A. How, Justin Moyers, Vivek Subbiah, David S. Hong, Aung Naing
Format: Article
Language:English
Published: Innovative Healthcare Institute 2025-04-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-24-27
Tags: Add Tag
No Tags, Be the first to tag this record!